Brief: Kiromic Biopharma Announces FDA Feedback From Type B Pre-Ind Meeting Confirms Deltacel Development Strategy
06/10/2022 13:51
Oct 6 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA ANNOUNCES FDA FEEDBACK FROM TYPE B
PRE-IND
MEETING CONFIRMS DELTACEL DEVELOPMENT STRATEGY
* KIROMIC BIOPHARMA INC- REITERATES DELTACEL IS NEXT
CLINICAL
TRIAL CANDIDATE, WITH PROJECTED CLINICAL TRIAL LAUNCH EXPECTED
IN Q1 2023
* KIROMIC BIOPHARMA INC - STREAMLINING OPERATIONS TO EXECUTE
DELTACEL-ALIGNED DEVELOPMENT STRATEGY
* KIROMIC BIOPHARMA INC - TO ELIMINATE 20 POSITIONS OR
APPROXIMATELY 29% OF ITS WORKFORCE
* KIROMIC BIOPHARMA INC- DECISION TO ELIMINATE 20 POSITIONS
OR
APPROXIMATELY 29% OF ITS WORKFORCE
* KIROMIC- LEVERAGE FDA PRE-IND WRITTEN CONFIRMATORY
FEEDBACK,RECOMMENDATIONS INTO IND SUBMISSION PACKAGE FOR
PROJECTED CLINICAL TRIAL LAUNCH IN Q1 2023
Source text for Eikon: ID:nBw26nnRna
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site